Flexion Therapeutics, Inc. (NASDAQ:FLXN) insider Yamo Deniz acquired 1,375 shares of Flexion Therapeutics stock in a transaction that occurred on Thursday, August 31st. The stock was acquired at an average price of $25.40 per share, with a total value of $34,925.00. Following the completion of the purchase, the insider now directly owns 5,000 shares in the company, valued at approximately $127,000. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Yamo Deniz also recently made the following trade(s):

  • On Tuesday, September 5th, Yamo Deniz acquired 1,000 shares of Flexion Therapeutics stock. The stock was acquired at an average price of $24.20 per share, with a total value of $24,200.00.
  • On Friday, September 1st, Yamo Deniz acquired 3,000 shares of Flexion Therapeutics stock. The stock was acquired at an average price of $24.15 per share, with a total value of $72,450.00.

Flexion Therapeutics, Inc. (NASDAQ FLXN) traded up 2.16% on Friday, hitting $24.12. 732,733 shares of the stock were exchanged. Flexion Therapeutics, Inc. has a 12 month low of $15.88 and a 12 month high of $29.41. The firm’s market cap is $769.55 million. The company has a 50-day moving average of $23.24 and a 200 day moving average of $21.99.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.11). Equities research analysts expect that Flexion Therapeutics, Inc. will post ($3.70) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Insider Buying: Flexion Therapeutics, Inc. (FLXN) Insider Purchases 1,375 Shares of Stock” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was illegally copied and republished in violation of international copyright and trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/15/insider-buying-flexion-therapeutics-inc-flxn-insider-purchases-1375-shares-of-stock.html.

A number of research analysts recently weighed in on FLXN shares. Northland Securities started coverage on shares of Flexion Therapeutics in a research note on Thursday, August 24th. They issued an “outperform” rating and a $40.00 price objective for the company. Royal Bank Of Canada restated a “buy” rating and set a $44.00 price target on shares of Flexion Therapeutics in a research report on Friday, July 7th. Zacks Investment Research lowered shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Cantor Fitzgerald set a $40.00 price target on shares of Flexion Therapeutics and gave the company a “buy” rating in a research report on Monday, May 22nd. Finally, BMO Capital Markets restated a “buy” rating on shares of Flexion Therapeutics in a research report on Tuesday, June 27th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $31.50.

Several hedge funds have recently made changes to their positions in FLXN. Teachers Advisors LLC raised its position in shares of Flexion Therapeutics by 21.2% during the 4th quarter. Teachers Advisors LLC now owns 43,468 shares of the specialty pharmaceutical company’s stock valued at $827,000 after purchasing an additional 7,610 shares during the period. Janney Montgomery Scott LLC raised its position in shares of Flexion Therapeutics by 30.8% during the 1st quarter. Janney Montgomery Scott LLC now owns 13,575 shares of the specialty pharmaceutical company’s stock valued at $365,000 after purchasing an additional 3,200 shares during the period. Wells Fargo & Company MN raised its position in shares of Flexion Therapeutics by 25.1% during the 1st quarter. Wells Fargo & Company MN now owns 124,717 shares of the specialty pharmaceutical company’s stock valued at $3,356,000 after purchasing an additional 25,047 shares during the period. Canada Pension Plan Investment Board bought a new stake in shares of Flexion Therapeutics during the 1st quarter valued at $2,018,000. Finally, Bank of New York Mellon Corp raised its position in shares of Flexion Therapeutics by 9.0% during the 1st quarter. Bank of New York Mellon Corp now owns 2,124,208 shares of the specialty pharmaceutical company’s stock valued at $57,163,000 after purchasing an additional 175,879 shares during the period. Hedge funds and other institutional investors own 82.75% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Insider Buying and Selling by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.